BeiGene inks $60M licensing, research pacts with Zymeworks; Merck, AbbVie, Amgen back neuro upstart
→ The savvy dealmakers at Zymeworks $ZYME have scored another heavyweight partner as BeiGene signs on for regional rights to two of its early-stage assets and the opportunity to develop three more on its antibody platforms.
Between two licensing deals, the Chinese cancer drugmaker $BGNE is paying $60 million in cash and dedicating up to $1.09 billion collectable at various stops of the long development and commercialization path.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.